Fragment-Based Drug Discovery Market Size, Share & Trends Analysis Report By Service Components (Fragment Screening, Fragment Optimization), By End-User (Biopharmaceutical Companies, CROs, Academic and Research Institutions), By Applications (Oncology, Central Nervous System (CNS) Disorders, Infectious Diseases, Cardiovascular Diseases, Metabolic Disorders, Inflammation and Autoimmune Diseases) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Fragment-Based Drug Discovery Market Size

The global fragment-based drug discovery market size was valued at USD 969.27 million in 2025 and is projected to grow from USD 1080.74 million in 2026 to USD 2581.78 million by 2034, registering a CAGR of 11.5% during the forecast period from 2026 to 2034. North America dominated the fragment-based drug discovery market with a market share of 41.2% in 2025.

Key drivers in the global Fragment-Based Drug Discovery (FBDD) market include advancements in structural biology techniques, enabling more efficient identification of fragment hits for drug targets. Moreover, the escalating demand for novel and effective therapeutics and the rising prevalence of chronic diseases fuels the adoption of FBDD as a viable drug discovery approach.

Fragment-based drug discovery (FBDD) is a method to develop potent small-molecule compounds starting from fragments that bind weakly to targets. FBDD has several advantages over high-throughput screening campaigns, such as saving experimental costs, offering diverse hits, and exhibiting multiple ways to develop novel compounds. FBDD has been applied to targets such as enzymes, protein-protein interactions, and membrane proteins.

FBDD usually involves the following steps: selecting a fragment library, screening for hits using sensitive biophysical methods, determining the structures of fragment-target complexes, developing assays for analyzing structure-activity relationship (SAR), and designing strategies to grow or link the fragments into drug-like lead compounds. FBDD has become a widely used approach in target-based drug discovery and has contributed to discovering several approved drugs and clinical candidates.

Service Components Analysis

Fragment optimization of the service component segment is the dominant segment in the Fragment-Based Drug Discovery Market because it involves the improvement of the binding affinity, selectivity, and physicochemical properties of the initial fragment hits. Fragment optimization is a crucial step in drug discovery, as it transforms weak and non-drug-like fragments into potent and drug-like lead compounds. Fragment optimization requires the application of various biophysical techniques, computational methods, and medicinal chemistry principles to achieve the desired optimization goals. It provides a valuable and efficient service for the development of novel and effective drugs for various therapeutic areas. Therefore, fragment optimization of the service component segment is dominant in the Fragment-Based Drug Discovery Market.

Request Customizationto receive a tailored report.

End-Users Analysis

Biopharmaceutical companies of the end-user segment as a dominant segment in the fragment-based drug discovery market is the increasing demand for novel and effective drugs for various therapeutic areas, such as oncology, central nervous system disorders, infectious diseases, cardiovascular diseases, metabolic disorders, and inflammation and autoimmune diseases. Fragment-based drug discovery offers several advantages for biopharmaceutical companies, such as reducing the cost and time of drug discovery, exploring new chemical space and binding modes, targeting challenging and unexplored protein classes, and enhancing the potency and selectivity of lead compounds. Biopharmaceutical companies are the primary consumers of fragment-based drug discovery services, as they use this approach to identify and optimize lead compounds for their drug development pipelines.

Application Analysis

Oncology is one of the dominant segments in the fragment-based drug discovery (FBDD) market, as it is a major therapeutic area with high unmet medical needs and a large patient population. FBDD can offer a novel and efficient way to discover new drugs for cancer, as it can target challenging and unexplored protein classes, such as protein-protein interactions, allosteric sites, and membrane proteins, and can reduce the cost and time of drug discovery, which are major barriers for developing drugs for oncology. FBDD can benefit from the availability of natural products, which are rich sources of diverse and complex fragments that can modulate biological targets involved in oncology.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America Dominates the Global Market

North America is the most significant global fragment-based drug discovery market shareholder and is expected to expand substantially during the forecast period. This is due to the many biopharmaceutical companies actively involved in drug discovery and development for various therapeutic areas, such as central nervous system disorders, oncology, infectious diseases, etc. These companies use fragment-based drug discovery as a complementary or alternative approach to conventional methods, such as high-throughput screening and structure-based drug design, to identify novel and potent lead compounds. It also has a strong presence of academic and research institutions collaborating with industry players and providing fragment screening and optimization services. These institutions have access to advanced biophysical techniques and technologies, such as X-ray crystallography, nuclear magnetic resonance, surface plasmon resonance, and others that enable efficient and accurate detection and characterization of fragment-target interaction.

The Food and Drug Administration incentives and programs for rare and neglected diseases are designed to facilitate and accelerate drug development for these conditions, which often have limited or no effective treatments. The FDA offers various incentives and programs to encourage and facilitate the discovery and development of new drugs for rare and neglected diseases, which affect millions of people worldwide but have limited or no effective treatments available. These include orphan drug designation, fast track designation, priority review designation, breakthrough therapy designation, rare pediatric disease designation, orphan product grants program, and rare neurodegenerative disease grant program. These incentives and programs provide benefits such as tax credits, user fee waivers, market exclusivity, priority review, accelerated approval, funding for clinical trials and natural history studies, and guidance on efficient drug development. By providing these incentives and programs, the FDA aims to enhance patients' health and quality of life with rare and neglected diseases and address their unmet medical needs.

Moreover, the discovery of a novel inhibitor of KRAS G12C, a mutant protein that drives several types of cancer, by a team of researchers from Amgen, Astex Pharmaceuticals, and the University of California, San Francisco. The inhibitor, named AMG 510, was identified using a combination of fragment screening, structure-based design, and medicinal chemistry optimization. AMG 510 is the first covalent inhibitor of KRAS G12C to enter clinical trials and has shown promising results in patients with non-small cell lung cancer and colorectal cancer.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia-Pacific: Significantly Growing Region

The Asia-Pacific is projected to grow significantly over the forecast period. Its growing population increases the demand for new and effective drugs for various diseases and conditions. The region has a high prevalence of infectious and chronic diseases, such as tuberculosis, malaria, diabetes, and cancer, which require novel and innovative therapies. The region has a favorable regulatory environment that supports the approval and commercialization of new drugs. For example, China has implemented reforms to speed up the drug review and approval process, such as accepting foreign clinical trial data and granting priority review for innovative drugs. Moreover, the region has a low drug discovery and development cost, attracting foreign investments and collaborations. For example, India has a large pool of skilled and qualified scientists, engineers, and technicians offering high-quality and cost-effective service for fragment-based drug discovery.

List of Key and Emerging Players in Fragment-Based Drug Discovery Market